Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 6749069

Thyroid replacement in thyroparathyroidectomized dogs.

H N Hulter·L E Gustafson·E L Bonner·R D Toto·S Mackie
View original source ↗Export metadata ↓

Abstract

The thyroparathyroidectomized dog is an important experimental model of hypoparathyroidism and has been widely utilized for acute and chronic studies of the physiologic role of parathyroid hormone on systemic and renal acid-base, electrolyte and vitamin D physiology. Despite widespread use of this model, the appropriate thyroid hormone replacement dose necessary for achievement of postoperative euthyroidism has not been established for this species. Accordingly, serum thyroxine (T4) concentration was measured prior to and following chronic thyroparathyroidectomy in dogs given thyroid hormone replacement at different doses and routes of administration: sodium levothyroxine, 2.4 micrograms/kg daily in one or two divided subcutaneous doses (group I, n = 9), 20 micrograms/kg daily in two divided oral doses (group II, n = 8), and a wide range of intravenous doses (group III, n = 3). Group I dosage was based on the reported T4 production rate in dogs and is slightly greater than the reported production rate in man. Group II dosage was based on published clinically derived estimates of required replacement amounts. With subcutaneous replacement (group I) serum T4 concentration decreased from a preoperative value of 1.80 +/- 0.20 to 0.60 +/- 0.10 microgram/100 ml (p less than 0.001) following thyroparathyroidectomy. With oral replacement (group II), serum T4 concentration after thyroparathyroidectomy was not significantly changed from control (1.88 +/- 0.22 vs. 1.66 +/- 0.43 microgram/100 ml). Group III studies revealed that both total and free serum T4 concentration could be normalized after thyroparathyroidectomy with an intravenous dose of 10 micrograms/kg daily. As found with subcutaneous administration, intravenous replacement with lesser amounts of T4 than 10 micrograms/kg daily (i.e. 2.5 micrograms/kg) resulted in significant decreases in serum T4 concentration from control.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

Administration, OralAnimalsDisease Models, AnimalDogsFemaleHypoparathyroidismHypothyroidismInjections, IntravenousInjections, SubcutaneousParathyroid GlandsThyroidectomyThyroxineJournal ArticleResearch Support, U.S. Gov't, Non-P.H.S.Research Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H N Hulter, L E Gustafson, E L Bonner, R D Toto, S Mackie. 1984. Thyroid replacement in thyroparathyroidectomized dogs.. https://pubmed.ncbi.nlm.nih.gov/6749069/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Water-based nanoparticulate polymeric system for protein delivery: permeability control and vaccine application.

The idea of using polymeric nanoparticles as drug carriers is receiving an increasing amount of attention both in academia and industry, Nanoparticles have a number of potential applications in protein, drug and vaccine delivery, as well as gene therapy applications. In this article, we focus on this unique drug delivery technology as a method to control the release rate of substances, not only for protein delivery but also for delivering an experimental vaccine immunogen. Nanoparticles were assembled on the basis of ionic interaction between water-soluble polymers so that the resulting particles were stable in physiologic media. Among the typical polymers used to assemble nanoparticles, different polysaccharides, natural amines, and poly-amines were investigated. The entrapped substances tested included a protein and antigens. Polydextran aldehyde was incorporated into the particle core, to enable physiologic cross-linking as a method to control permeability. This resulted in long-term retention of substances that would otherwise rapidly leak out of the nanoparticles. Results of cross-linking experiments clearly demonstrated that the release rate could be substantially reduced, depending on the degree of cross-linking. For vaccine antigen delivery tests, we measured an antibody production after subcutaneous and oral administration. The data indicated that only the cross-linked antigen was immunogenic when the oral route of administration was used. The data presented in this article address primarily the utility of nanoparticulates for oral delivery of vaccine antigen.

Administration, Oral↗
PubMed2002

CD1-dependent natural killer (NK1.1(+)) T cells are required for oral and portal venous tolerance induction.

BACKGROUND: Local antigen presentation via either the oral (PO) or the portal venous (PV) routes results in suppression of systemic delayed-type hypersensitivity (DTH). The responsible cell populations are not well defined. Because NK1.1(+) T cells express the Fas ligand and produce high levels of the immunosuppressive cytokine, IL-4, they may play a role in both activated T-cell apoptosis and a Th1 to Th2 immune shift, thus promoting tolerance induction. METHODS: C57BL/6 mice were tolerized to BALB/c alloantigen by PV or PO spleen cells (25 x 10(6)) on Day 0. Subcutaneous (SQ) challenge with 10 x 10(6) BALB/c cells on Day 7 was followed by footpad injection of 10 x 10(6) BALB/c cells on Day 14. Footpad swelling was measured 24 h later. A single injection of the NK1.1(+) cell-depleting antibody, PK-136, was given IP (10 mg/kg) 2 days prior to PV or PO antigen. Flow cytometry evaluated NK1.1(+) cell depletion. CD1 knockout (KO) mice, lacking NK1.1(+) T cells, were also challenged with PV and PO Balb/c in parallel experiments. RESULTS: The DTH to BALB/c antigen was markedly suppressed in C57BL/6 mice when this alloantigen was given by either PO or PV routes (P < 0.001, P < 0.001). The maintenance of an unaltered response to third-party C3H/HeJ demonstrated alloantigenic specificity. Administration of the anti-NK1.1 T cell monoclonal antibody, PK-136, resulted in complete restoration of in vivo DTH responsiveness in PO tolerance (P < 0.01), and partial restoration in PV tolerance (P < 0.05) in C57BL/6 mice. FACS confirmed virtually complete depletion of liver, splenic, Peyer's patch, and mesenteric lymph node NK1.1(+) lymphocytes. Development of both PO and PV tolerance was prevented in CD1 KO mice. CONCLUSION: NK1.1(+) T cells play an essential role in antigen-specific suppression of the DTH response mediated by both oral and portal venous tolerance.

Administration, Oral↗
PubMed2002

Dichloroacetate toxicokinetics and disruption of tyrosine catabolism in B6C3F1 mice: dose-response relationships and age as a modifying factor.

Dichloroacetate (DCA) is a rodent carcinogen commonly found in municipal drinking water supplies. Toxicokinetic studies have established that elimination of DCA is controlled by liver metabolism, which occurs by the cytosolic enzyme glutathione-S-transferase-zeta (GST-zeta). DCA is also a mechanism based inhibitor of GST-zeta, and a loss in GST-zeta enzyme activity occurs following repeated doses or prolonged drinking water exposures. GST-zeta is identical to an enzyme that is part of the tyrosine catabolism pathway known as maleylacetoacetate isomerase (MAAI). In this pathway, GST-zeta plays a critical role in catalyzing the isomerization of maleylacetoacetate to fumarylacetoacetate. Disruption of tyrosine catabolism has been linked to increased cancer risk in humans. We studied the elimination of i.v. doses of DCA to young (10 week) and aged (60 week) mice previously treated with DCA in their drinking water for 2 and 56 weeks, respectively. The diurnal change in blood concentrations of DCA was also monitored in mice exposed to three different drinking water concentrations of DCA (2.0, 0.5 and 0.05 g/l). Additional experiments measured the in vitro metabolism of DCA in liver homogenates prepared from treated mice given various recovery times following treatment. The MAAI activity was also measured in liver cytosol obtained from treated mice. Results indicated young mice were the most sensitive to changes in DCA elimination after drinking water treatment. The in vitro metabolism of DCA was decreased at all treatment rates. Partial restoration ( approximately 65% of controls) of DCA elimination capacity and hepatic GST-zeta activity occurred after 48 h recovery from 14 d 2.0 g/l DCA drinking water treatments. Recovery from treatments could be blocked by interruption of protein synthesis with actinomycin D. MAAI activity was reduced over 80% in liver cytosol from 10-week-old mice. However, MAAI was unaffected in 60-week-old mice. These results indicate that in young mice, inactivation and re-synthesis of GST-zeta is a highly dynamic process and that exogenous factors that deplete or reduce GST-zeta levels will decrease DCA elimination and may increase the carcinogenic potency of DCA. As mice age, the elimination capacity for DCA is less affected by reduced liver metabolism and mice appear to develop some toxicokinetic adaptation(s) to allow elimination of DCA at rates comparable to naive animals. Reduced MAAI activity alone is unlikely to be the carcinogenic mode of action for DCA and may in fact, only be important during the early stages of DCA exposure.

Administration, Oral↗